Readystate Asset Management LP Purchases 143,142 Shares of uniQure N.V. $QURE

Readystate Asset Management LP increased its position in shares of uniQure N.V. (NASDAQ:QURE) by 39.6% during the first quarter, Holdings Channel reports. The institutional investor owned 504,702 shares of the biotechnology company’s stock after purchasing an additional 143,142 shares during the period. Readystate Asset Management LP’s holdings in uniQure were worth $8,252,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. CIBC Private Wealth Group LLC acquired a new stake in uniQure in the third quarter valued at approximately $50,000. Torren Management LLC acquired a new position in shares of uniQure during the fourth quarter worth approximately $28,000. IFP Advisors Inc acquired a new position in shares of uniQure during the fourth quarter worth approximately $48,000. Smartleaf Asset Management LLC bought a new position in shares of uniQure in the 4th quarter worth $48,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of uniQure by 42.7% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,027 shares of the biotechnology company’s stock worth $72,000 after purchasing an additional 906 shares in the last quarter. Institutional investors own 78.83% of the company’s stock.

uniQure Trading Down 4.1%

NASDAQ QURE opened at $36.66 on Wednesday. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33. The business has a fifty day simple moving average of $36.44 and a 200 day simple moving average of $25.89. uniQure N.V. has a 12 month low of $8.73 and a 12 month high of $71.50. The firm has a market capitalization of $2.31 billion, a P/E ratio of -10.53 and a beta of 0.90.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The firm had revenue of $3.56 million for the quarter, compared to the consensus estimate of $5.21 million. On average, analysts predict that uniQure N.V. will post -3.39 EPS for the current fiscal year.

Insider Activity at uniQure

In related news, insider Walid Abi-Saab sold 45,000 shares of the business’s stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $25.06, for a total transaction of $1,127,700.00. Following the transaction, the insider directly owned 169,669 shares in the company, valued at approximately $4,251,905.14. The trade was a 20.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kylie O’keefe sold 15,936 shares of the stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $27.06, for a total transaction of $431,228.16. Following the completion of the sale, the insider owned 108,864 shares of the company’s stock, valued at approximately $2,945,859.84. This trade represents a 12.77% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 433,229 shares of company stock valued at $17,944,799 over the last three months. Insiders own 4.65% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on QURE. Stifel Nicolaus set a $28.00 price target on shares of uniQure in a research note on Tuesday, May 5th. Mizuho raised their price objective on shares of uniQure from $35.00 to $68.00 and gave the company an “outperform” rating in a research note on Thursday, June 25th. Barclays upgraded shares of uniQure from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $25.00 to $65.00 in a report on Thursday, June 18th. Cantor Fitzgerald raised shares of uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 target price for the company in a research report on Wednesday, June 17th. Finally, Chardan Capital upped their target price on shares of uniQure from $31.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Twelve investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, uniQure has an average rating of “Moderate Buy” and a consensus price target of $64.17.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.